Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera

Virology

Volumn 220, Issue 2, 1996, Pages 450-460

  McKeating, Jane A ^a   Zhang, Yi Jin ^b   Arnold, Cath ^c   Frederiksson, Robert ^b   Fenyö, Eva Maria ^b   Balfe, Peter ^d  

^a UNIVERSITY OF READING   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029894603     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0332     Document Type: Article

References (66)

1. Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nyström, G., and Fenyö, E-M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112.
2. Albert, J., Björling, E., von Gegerfelt, A., Scarlatti, G., Zhang, Y-J., and Fenyö, E-M. (1993). Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res. Hum. Retroviruses 9, 501-504.
3. Arnold, C., Balfe, P., and Clewley, J. P. (1995). Sequence distances between envgenes from individuals infected from the same source: Implications for the investigation of possible transmission events. Virology 211, 198-203.
4. Ashkenazi, A., Smith, D. H., Marsters, S. A., Riddle, L., Gregory, T. J., Ho, D. D., and Capon, D. J. (1991). Resistance of primary HIV-1 isolates to soluble CD4 is independent of CD4-gp120 binding affinity. Proc. Natl. Acad. Sci. USA 88, 7056-7060.
5. Åsjö, B., Morfeldt-Manson, L., Albert, J., Biberfeld, G., Karlsson, A., Lidman, K., and Fenyö, E M. (1986). Replicative properties of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet ii, 660-662.
6. Boucher, C. A. B., Lange, J. M. A., Miedema, F., Weverling, G. J., Koot, M., Mulder, J. W., Goudsmit, J., Kellam, P., Larder, B., and Tersmette, M. (1992). HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 6, 1259-1264.
7. Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P., and Norcross, M. A. (1995). Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immnuodeficiecny virus type 1 from antibody neutralization. J. Virol. 69, 6006-6013.
8. Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A., Purtscher, M., Gruber, G., Tauer, C., Steinndl, F., Jungbauer, A., and Kattinger, H. (1994). Electrofusion and EBV transformation for PBL immortalization: Generation of human monoclonal antibodies against HIV-1 proteins. AIDS. Res. Hum. Retroviruses 10, 359-369.
9. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, E., Stiehm, E. R., Bryson, Y. J., Moore, J. P., Ho, D. D., and Barbas, C. F., III (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
10. Cao, Y., Zhang, L. Q., Safrit, J., and Ho, D. D. (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201-208.
11. Cheng-Mayer, C., Seto, D., Tateno, M., and Levy, J. A. (1988). Biologic features of HIV-1 that correlate with virulence in the host. Science 240, 80-82.
12. Clapham, P. R., McKnight, A., and Weiss, R. A. (1992). Human immuno-deficiency virus type 2 infection and fusion of CD4-negative cell lines: Induction and enhancement by soluble CD4. J. Virol. 66, 3531-3537.
13. Conley, A. J., Gorny, M. K., Kessler, J. A., II, Boots, L. J., Ossorio-Castro, M., Koenig, S., Lineberger, D. W., Emini, E. A., Williams, C., and Zolla-Pazner, S. (1994a). Neutralization of primary human immunodeficiency virus type I isolates bythe broadly reactive anti-V3 monoclonal antibody. J. Virol. 68, 6994-7000.
14. Conley, A. J., Kessler, J. A., II, Boots, L. J., Tung, J.-S., Arnold, B. A., Keller, P. M., Shaw, A. R., and Emini, E. A. (1994b). Neutralization of divergent human immunodeficiency virus type I variants and primary isolates by IAM-412-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91, 3348-3352.
15. Connor, R. I., and Ho, D. D. (1994). Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 68, 4400-4408.
16. Cordell, J., Moore, J. P., Dean, C. J., Klasse, P. J., Weiss, R. A., and McKeating, J. A. (1991). Rat monoclonal antibodies to non-overlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology 185, 72-79.
17. De-Jong, J. J., De-Ronde, A., Keulen, W., Tersmette, M., and Goudsmit, J (1992). Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J. Virol. 66, 6777-6780
18. Earl, P. L., Broder, C. C., Long, D., Lee, S., Peterson, J., Chakrabarti, S., Doms, R. W., and Moss, B. (1994). Native oligomeric human immunodeficiency virus type I envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68, 3015-3026.
19. Fenyö, E-M., Morfeldt-Månson, L., Chiodi, F., Lind, A., von Gegerfelt, A., Albert, J., Qausson, E., and Åsjö, B. (1988). Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62, 4414-4419.
20. Fredriksson, R., Stålhandske, P., von Gegerfelt, A., Lind, B., Åman, P., Rassart, E., and Fenyö, E-M. (1991). Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity. Virology 181, 55-61.
21. Gorny, M. K., Xu, J. Y., Gianakakos, V., and Zolla-Pazner, S. (1989). Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86, 1624-1628.
22. Groenink, M., Fouchier, R. A., Broersen, S., Baker, C. H., Koot, M., van't-Wout, A. B., Huisman, H. G., Miedema, F., Tersmette, M., and Schuitemaker, H. (1993). Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260, 1513-1516.
23. Hammond, A., Lewis, J., May, J., Albert, J., Balfe, P., and McKeating, J. A. (1995). Manuscript in preparation.
24. Helseth, E., Olshevsky, U., Furman, C., and Sodroski, J. (1991). Human immunodeficiency type I gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol. 65, 2119-2123.
25. Ho, D. D., McKeating, J. A., Li, X. L., Moudgil, T., Daar, E. S., Sun, N. C., and Robinson, J. E. (1991). Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65, 489-493.
26. Kabat, D., Kozak, S. L., Wehrly, K., and Chesebro, B. (1994). Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 68, 2570-2577.
27. Kattinger, H. (1994). Human monoclonal antibodies for passive immunization therapy of HIV-1. Antibiot. Chemother. 46, 25-37.
28. Klasse, P. J., McKeating, J. A., Schutten, M., Reitz, M. S., and Robert-Guroff, M. (1993). An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-ENV: Ala 582-Thr) decreases viral neutralization by monoclonal antibodies to the CD4 binding site. Virology 196, 332-337.
29. Koot, M., Vos, A. H. V., Keet, R. P. M., de Goede, R. E., Dercksen, M. W., Terpstra, F. G., Coutinho, R. A., Miedema, F., and Tersmette, M. (1992). HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 6, 49-54.
30. Kostrikis, L. G., Cao, Y., Ngai, H., Moore, J. P., and Ho, D. D. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70, 445-458.
31. Mascola, J. R. E., Louwagie, J., McCutcheon, F., Fisher, C. L., Hegerich, P. A., Wagher, K. F., Fowler, A. K., McNeil, J. G., and Burke, D. S. (1994). Two antigenically distinct subtypes of human immunodeficiency virus type I: Viral genotypes predict neutralization serotypes. J. Infect. Dis. 169, 48-54.
32. McKeating, J. A, McKnight, A., and Moore, J. P. (1990). Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type I isolates: Effect on infectivity and neutralization. J. Virol. 65, 852-860.
33. McKeating, J. A., Bennet, J., Zolla-Pazner, S., Schutten, M., Ashelford, S., Leigh Brown, A. J., and Balfe, P. (1993a). Resistance of a human serum selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J. Virol. 67, 5216-5225.
34. McKeating, J. A., Shotton, C., Cordell, J., Graham, S., Balfe, P., Sullivan, N., Charles, M., Page, M., Bolmstedt, A., Olofsson, S., Kayman, S. C., Wu, Z, Pinter, A., Dean, C., Sodroski, J., and Weiss, R. A. (1993b). Characterisation of neutralising monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type I gp120. J. Virol. 67, 5216-5225.
35. Modrow, S., Hahn, B. H., Shaw, G. M., Gallo, R C., Wong-Staal, F., and Wolf, H. (1987). Computer assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions. J. Virol. 61, 570-578.
36. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B., and Ho, D. D. (1996). Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic sub-types. J. Virol. 70, 427-444.
37. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R., and Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type I are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109.
38. Moore, J. P., McKeating, J. A., Huang, Y., Ashkenazi, A., and Ho, D. D. (1992). Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 neutralization differ in sCD4 binding and gp120 retention from sCD4-sensitive isolates. J. Virol. 66, 235-243.
39. Moore, J. P., McKeating, J. A., Jones, I. M., Stephens, P. E., Clements, G., Thomson, S., and Weiss, R. A. (1990). Characterisation of recombinant gp120 and gp160 from HIV-1: Binding to monoclonal antibodies and soluble CD4. AIDS 4, 307-315.
40. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ruker, F., and Kattinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type I. J. Virol. 67, 6642-6647.
41. Myers, G., Korber, B., and Pavlakis, G. (1993). "Human Retroviruses and AIDS." Theoretical Biology and Biophysics Group T-10, Los Alamos, NM.
42. Nei, M., and Gojobori, K. (1986). Simple methods for estimating the numbers of synonymous and non-synonymous nucleotide substitutions. Mol. Biol. Evol. 3, 418-426.
43. Palmer, C. P., Balfe, P., Albert, J., and McKeating, J. A. (1996). Functional characterisation of the V1V2 region of human immunodeficiency virus type I. Virology 220, 000-000.
44. Pantaleo, G, Menzo, S., Vaccarezza, M., Graziosi, C., Cohen, O. J., Schrager, L. K., Margolick, J. B., Buchbinder, S., Giorgi, J. V., and Fauci, A. S. (1995). Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216.
45. Reitz, M. S., Jr., Wilson, C., Naugle, C., Gallo, R. C., and Robert-Guroff, M. (1988). Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54, 57-63.
46. Sattentau, Q. J., Moore, J. P., Andeweg, A. C., Schutten, M., Osterhaus, A. D. M. E., and Schuitemaker, H. (1994). HIV-1 neutralization: Antibody-gp120 interactions. Neuvieme Colloque des Cent Gardes 135-139.
47. Sawyer, L. S. W., Wrin, M. T., Crawford-Miksa, L., Potts, B., Wu, Y., Weber, P. A., Alfonso, R. D., and Hanson, C. A. (1994). Neutralization sensitivity of human immunodeficiecny virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68, 1342-1349.
48. Scarlatti, G., Albert, J., Rossi, P., Hodara, V., Biraghi, P., Muggiasca, L., and Fenyö, E. M. (1993). Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168, 207-210.
49. Schuitemaker, H., Koot, M., Koostra, N. A., Dercksen, M. W., de Goede, R. E., van-Steenwijk, R. P., Lange, J. M., Schattenkerk, J. K., Miedema, F., and Tersmette, M.(1992). Biological phenotype of human immunodeficiency virus type I clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66, 1354-1360.
50. Schulz, T. F., Jameson, B. A., Lopalco, L., Siccardi, A. G., Weiss, R. A., and Moore, J. P. (1992). Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res. Hum. Retroviruses 8, 1571-1580.
51. Shotton, C., Arnold, C., Sattentau, Q. J., Sodroski, J., and McKeating, J. A. (1995). Identification and characterisation of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 69, 222-230.
52. Stamatos, L., and Cheng-Mayer, C. (1993). Evidence for the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J. Virol. 67, 5635-5639.
53. Stamatos, L., and Cheng-Mayer, C. (1995). Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion soluble receptor binding. J. Virol. 69, 6191-6198.
54. Steimer, K. S., Klasse, P. J., and McKeating, J. A. (1991). Human immunodeficiency virus type 1 neutralization directed to epitopes other than linear V3 determinants. AIDS 5, S135-143.
55. Sullivan, N., Sun, Y., Li, J., Hofmann, W., and Sodroski, J. (1995). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
56. Sundqvist, V. A., Albert, J., Ohlsson, E., Hinkula, J., Fenyö, E. M., and Wahren, B. (1989). Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J. Med. Virol. 29, 170-175.
57. Tan, W., Fredriksson, R., Björndal, Å., Balfe, P., and Fenyö, E. (1993). Cotransfection of HIV-1 molecular clones with restricted cell tropism may yield progeny virus with altered phenotype. AIDS Res. Hum. Retroviruses 9, 321-329.
58. Tersmette, M., Gruters, R. A., de Wolf, F., de-Goede, R. E., Lange, J. M., Schellekens, P. T., Goudsmit, J., Huisman, H. G., and Miedema-F., F. (1989). Evidence for a role of virulent human immunodeficiency virus variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J. Virol. 63, 2118-2125.
59. Thali, M., Charles, M., Furman, C., Cavacini, L., Posner, M., Robinson, J., and Sodrodski, J. (1994). Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type I gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68, 674-680.
60. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Kattinger, H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiecny virus type I. J. Virol. 70, 1100-1108.
61. Turner, S., Tizzard, R., DeMarinis, J., Pepinsky, R. B., Zullo, J., Schooley, R, and Fisher, R. (1992). Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 89, 1335-1339.
62. von Gegerfelt, A., Albert, J., Morfeldt-Månson, L., Broliden, K., and Fenyö, E. (1991). Isolate-specific neutralizing antibodies in patients with progressive HIV-1 related disease. Virology 185, 162-168.
63. Wang, N., Zhu, T., and Ho, D. D. (1995). Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type I: Lack of correlation with viral phenotype. J. Virol. 69, 2708-2715.
64. Weber, J., Fenyö, E. M., Nara, P., Beddows, S., Kaleebu, P., Bjorndal, A., and the WHO Network for HIV Isolation and Characterisation (1995). Neutralization serotypes of HIV-1 are not predicted by genetic sub-type. Submitted for publication.
65. Wilson, C., Reitz, M. S., J., Aldrich, K., Klasse, P. J., Blomberg, J., Gallo, R. C., and Robert-Guroff, M. (1990). The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type I does not constitute the neutralization epitope. J. Virol. 64, 3240-3248.
66. Wrin, T., Loh, T. P., Charron, J., Schuitemaker, H., and Nunberg, J. H. (1995). Adaption to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69, 39-48.